Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$15.6 million.

  • Cartesian Therapeutics' Cash from Operations fell 21394.35% to -$15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$63.2 million, marking a year-over-year decrease of 5824.37%. This contributed to the annual value of -$23.7 million for FY2024, which is 5372.65% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Cash from Operations of -$15.6 million as of Q3 2025, which was down 21394.35% from -$17.5 million recorded in Q2 2025.
  • Cartesian Therapeutics' Cash from Operations' 5-year high stood at $13.7 million during Q3 2024, with a 5-year trough of -$31.5 million in Q4 2021.
  • In the last 5 years, Cartesian Therapeutics' Cash from Operations had a median value of -$11.9 million in 2022 and averaged -$11.7 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Cash from Operations crashed by 33393.1% in 2021 and then surged by 24857.3% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Cash from Operations (Quarter) stood at -$31.5 million in 2021, then soared by 62.34% to -$11.8 million in 2022, then plummeted by 96.52% to -$23.3 million in 2023, then surged by 69.93% to -$7.0 million in 2024, then crashed by 122.79% to -$15.6 million in 2025.
  • Its Cash from Operations stands at -$15.6 million for Q3 2025, versus -$17.5 million for Q2 2025 and -$23.1 million for Q1 2025.